Evidence map›Paper›PMID 41233145›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

SIRPα Immuno-PET Provides a Pan-Myeloid View of Immune Activity During COVID-19.

Sridhar Nimmagadda

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Sridhar NimmagaddaRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland snimmag1@jhmi.edu.

Funding

Training/Dissemination-Resource for Molecular Imaging Agents in Precision MedicineP41EB024495 · NIBIB · UT SOUTHWESTERN MEDICAL CENTER · PI MARTIN G POMPER · 2017 to 2026
$11.8M
Clinical translation of a PD-L1 PET tracer to optimize immune checkpoint therapy in patients with non-small cell lung cancersR01CA269235 · NCI · JOHNS HOPKINS UNIVERSITY · PI Sridhar Nimmagadda, STEVEN P ROWE · 2022 to 2026
$3.2M
Non-invasive Quantification of Dose-Exposure-Response of PD-L1 Therapeutics at the TumorR01CA236616 · NCI · JOHNS HOPKINS UNIVERSITY · PI NIMMAGADDA, SRIDHAR · 2018 to 2022
$2.3M
NCI NIH HHS R01 CA236616NCI NIH HHS R01 CA269235NIBIB NIH HHS P41 EB024495
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41233145
PMCPMC12766883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.